Laporan Laba Rugi (TTM)
Laporan Laba Rugi Delta-Fly Pharma, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200 | 200 | 300 | 400 | 300 | 300 | 300 | 200 | 200 | 200 |
| Change (%) | 0.00 | 50.00 | 33.33 | -25.00 | 0.00 | 0.00 | -33.33 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||||||||
| Change (%) | ||||||||||
| % of Revenue | ||||||||||
| Gross Operating Profit | 200 | 200 | 300 | 400 | 300 | 300 | 300 | 200 | 200 | 200 |
| Change (%) | 0.00 | 50.00 | 33.33 | -25.00 | 0.00 | 0.00 | -33.33 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 232 | 242 | 253 | 297 | 289 | 286 | 287 | 262 | 263 | 270 |
| Change (%) | 4.31 | 4.55 | 17.39 | -2.69 | -1.04 | 0.35 | -8.71 | 0.38 | 2.66 | |
| % of Revenue | 116.00 | 121.00 | 84.33 | 74.25 | 96.33 | 95.33 | 95.67 | 131.00 | 131.50 | 135.00 |
| R&D | 1,221 | 1,020 | 866 | 973 | 921 | 895 | 940 | 865 | 921 | 1,051 |
| Change (%) | -16.46 | -15.10 | 12.36 | -5.34 | -2.82 | 5.03 | -7.98 | 6.47 | 14.12 | |
| % of Revenue | 610.50 | 510.00 | 288.67 | 243.25 | 307.00 | 298.33 | 313.33 | 432.50 | 460.50 | 525.50 |
| OpEx | 1,483 | 1,292 | 1,152 | 1,303 | 1,243 | 1,214 | 1,261 | 1,161 | 1,218 | 1,355 |
| Change (%) | -12.88 | -10.84 | 13.11 | -4.60 | -2.33 | 3.87 | -7.93 | 4.91 | 11.25 | |
| % of Revenue | 741.50 | 646.00 | 384.00 | 325.75 | 414.33 | 404.67 | 420.33 | 580.50 | 609.00 | 677.50 |
| Operating Income | -1,283 | -1,092 | -852 | -903 | -943 | -914 | -961 | -961 | -1,018 | -1,155 |
| Change (%) | -14.89 | -21.98 | 5.99 | 4.43 | -3.08 | 5.14 | -0.00 | 5.93 | 13.46 | |
| % of Revenue | -641.50 | -546.00 | -284.00 | -225.75 | -314.33 | -304.67 | -320.33 | -480.50 | -509.00 | -577.50 |
| Interest Expense | ||||||||||
| Change (%) | ||||||||||
| % of Revenue | ||||||||||
| Net Income | -1,288 | -1,096 | -862 | -915 | -955 | -926 | -967 | -969 | -1,032 | -1,168 |
| Change (%) | -14.91 | -21.35 | 6.15 | 4.37 | -3.04 | 4.43 | 0.21 | 6.50 | 13.18 | |
| % of Revenue | -644.00 | -548.00 | -287.33 | -228.75 | -318.33 | -308.67 | -322.33 | -484.50 | -516.00 | -584.00 |
Source: Capital IQ
